CY1119744T1 - Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων - Google Patents

Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων

Info

Publication number
CY1119744T1
CY1119744T1 CY20161100759T CY161100759T CY1119744T1 CY 1119744 T1 CY1119744 T1 CY 1119744T1 CY 20161100759 T CY20161100759 T CY 20161100759T CY 161100759 T CY161100759 T CY 161100759T CY 1119744 T1 CY1119744 T1 CY 1119744T1
Authority
CY
Cyprus
Prior art keywords
tumor
present
vaccine
relates
glioblastoma
Prior art date
Application number
CY20161100759T
Other languages
English (en)
Inventor
Oliver Schoor
Norbert Hilf
Toni Weinschenk
Claudia Trautwein
Steffen Walter
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CY1119744T1 publication Critical patent/CY1119744T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με πεπτίδια, νουκλεϊκά οξέα και κύτταρα για χρήση σε ανοσοθεραπευτικές μεθόδους. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με την ανοσοθεραπεία του καρκίνου. Η παρούσα εφεύρεση σχετίζεται επιπλέον με όγκο-σχετιζόμενους πεπτιδικούς επιτόπους κυτταροτοξικών Τ-κυττάρων (cytotoxic Τ lymphocytes -CTL), μεμονωμένους ή σε συνδυασμό με άλλα ογκο-σχετιζόμενα πεπτίδια, οι οποίοι λειτουργούν ως ενεργά φαρμακευτικά συστατικά συνθέσεων εμβολίων που διεγείρουν αντικαρκινικές ανοσοαπαντήσεις. Η παρούσα εφεύρεση σχετίζεται με 30 πεπτιδικές αλληλουχίες και τις παραλλαγές τους που προέρχεται από μόρια HLA τάξης I και II ανθρώπινων καρκινικών κυττάρων που μπορούν να χρησιμοποιηθούν σε συνθέσεις εμβολίων για να επιφέρουν αντικαρκινικές ανοσοαπαντήσεις.
CY20161100759T 2008-10-01 2016-08-02 Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων CY1119744T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
EP08017921.1A EP2172212B1 (en) 2008-10-01 2008-10-13 Novel immunotherapy against several tumors including neuronal and brain tumors
US10592808P 2008-10-16 2008-10-16
PCT/EP2009/006980 WO2010037514A2 (en) 2008-10-01 2009-09-28 Novel immunotherapy against several tumors including neuronal and brain tumors
EP09778750.1A EP2341927B1 (en) 2008-10-01 2009-09-28 Composition comprising tumor associated peptides and a vaccine for treatment of glioblastoma and other cancers

Publications (1)

Publication Number Publication Date
CY1119744T1 true CY1119744T1 (el) 2018-06-27

Family

ID=40342382

Family Applications (11)

Application Number Title Priority Date Filing Date
CY20151100139T CY1116302T1 (el) 2008-10-01 2015-02-12 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY20161100759T CY1119744T1 (el) 2008-10-01 2016-08-02 Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
CY20171100124T CY1118702T1 (el) 2008-10-01 2017-01-26 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY181101403T CY1121098T1 (el) 2008-10-01 2018-12-28 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20191100182T CY1121258T1 (el) 2008-10-01 2019-02-12 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100073T CY1122677T1 (el) 2008-10-01 2020-01-28 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100449T CY1122913T1 (el) 2008-10-01 2020-05-15 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100594T CY1123089T1 (el) 2008-10-01 2020-06-26 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100606T CY1123098T1 (el) 2008-10-01 2020-06-30 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100613T CY1123113T1 (el) 2008-10-01 2020-07-03 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100984T CY1123526T1 (el) 2008-10-01 2020-10-19 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20151100139T CY1116302T1 (el) 2008-10-01 2015-02-12 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου

Family Applications After (9)

Application Number Title Priority Date Filing Date
CY20171100124T CY1118702T1 (el) 2008-10-01 2017-01-26 Συνθεση πεπτιδιων που σχετιζονται με ογκους και σχετικου αντικαρκινικου εμβολιου για τη θεραπεια του γλοιοβλαστωματος (glioblastoma, gbm) και αλλων μορφων καρκινου
CY181101403T CY1121098T1 (el) 2008-10-01 2018-12-28 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20191100182T CY1121258T1 (el) 2008-10-01 2019-02-12 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100073T CY1122677T1 (el) 2008-10-01 2020-01-28 Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100449T CY1122913T1 (el) 2008-10-01 2020-05-15 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100594T CY1123089T1 (el) 2008-10-01 2020-06-26 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY20201100606T CY1123098T1 (el) 2008-10-01 2020-06-30 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου
CY20201100613T CY1123113T1 (el) 2008-10-01 2020-07-03 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων των νευρωνων και του εγκεφαλου
CY20201100984T CY1123526T1 (el) 2008-10-01 2020-10-19 Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων ογκων των νευρωνων και του εγκεφαλου

Country Status (25)

Country Link
US (19) US8318677B2 (el)
EP (12) EP2172211B1 (el)
JP (10) JP5855940B2 (el)
KR (6) KR102133402B1 (el)
CN (3) CN102170900B (el)
AU (2) AU2009300087B2 (el)
BR (2) BRPI0920791B8 (el)
CA (9) CA2936920C (el)
CY (11) CY1116302T1 (el)
DK (12) DK2172211T3 (el)
EA (3) EA023378B1 (el)
ES (12) ES2536465T3 (el)
HK (2) HK1159526A1 (el)
HR (12) HRP20201025T8 (el)
HU (11) HUE031030T2 (el)
LT (10) LT2172212T (el)
MX (3) MX338294B (el)
NZ (4) NZ591855A (el)
PL (12) PL2172211T3 (el)
PT (12) PT2172211E (el)
RS (12) RS53782B1 (el)
SI (12) SI2172211T1 (el)
TR (2) TR201900809T4 (el)
UA (3) UA110599C2 (el)
WO (2) WO2010037514A2 (el)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2012079878A2 (en) * 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AU2008281015B2 (en) * 2007-07-27 2012-07-26 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
RS53782B1 (en) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
MX353165B (es) * 2010-08-24 2017-12-20 Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2012075490A2 (en) * 2010-12-03 2012-06-07 Duke University Anti-podoplanin antibodies and methods of use
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
US9889209B2 (en) 2011-09-14 2018-02-13 Northwestern University Nanoconjugates able to cross the blood-brain barrier
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
CA2862706C (en) 2012-01-20 2021-08-03 Dennis Brown Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
ES2967342T3 (es) 2012-05-16 2024-04-29 Stemline Therapeutics Inc Vacunas contra el cáncer dirigidas a células madre cancerosas
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
TWI777198B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
RS62602B1 (sr) 2013-08-05 2021-12-31 Immatics Biotechnologies Gmbh Nova imunoterapija za lečenje nekoliko tumora, kao što je rak pluća, uključujući nsclc
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
NZ725169A (en) 2014-04-25 2018-02-23 Bluebird Bio Inc Mnd promoter chimeric antigen receptors
WO2015182668A1 (ja) * 2014-05-28 2015-12-03 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
CA2951044C (en) 2014-06-06 2023-10-03 Bluebird Bio, Inc. Improved t cell compositions
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
BR112017009358A2 (pt) * 2014-11-06 2017-12-19 Ose Immunotherapeutics imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo
EP3971210A1 (en) 2014-12-12 2022-03-23 2seventy bio, Inc. Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HUE046641T2 (hu) * 2014-12-23 2020-03-30 Immatics Biotechnologies Gmbh Új peptidek és peptidkombinációk hepatocelluláris karcinóma (HCC) és más rákok elleni immunoterápiában történõ alkalmazásra
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
IL308202A (en) * 2015-05-06 2024-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides and their supporters for the use of immunotherapy against colon tumors and other types of cancer
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
US11305002B2 (en) 2015-06-09 2022-04-19 The Board Of Regents Of The University Of Oklahoma Compositions and treatments for Haemophilus influenzae
EP3868406A1 (en) 2015-06-24 2021-08-25 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EA201792671A1 (ru) * 2015-07-06 2018-06-29 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака пищевода и других видов рака
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI782433B (zh) 2015-08-28 2022-11-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US10709758B2 (en) 2015-09-03 2020-07-14 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
MX2018007204A (es) 2015-12-16 2018-12-11 Gritstone Oncology Inc Identificacion, fabricacion y uso de neoantigeno.
WO2017123996A1 (en) 2016-01-15 2017-07-20 City Of Hope Targeting glioblastoma stem cells through the tlx-tet3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
DK3430037T3 (da) 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
MA44605A (fr) * 2016-04-06 2019-02-13 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre la leucémie myéloïde aiguë (lma) et d'autres cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
CA3034983A1 (en) * 2016-10-03 2018-04-12 Ottawa Hospital Research Institute Compositions and methods for enhancing growth, spread, and oncolytic and immunotherapeutic efficacy of oncolytic rna viruses
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
US10174122B2 (en) 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) * 2017-02-28 2018-09-07 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
US11504421B2 (en) * 2017-05-08 2022-11-22 Gritstone Bio, Inc. Alphavirus neoantigen vectors
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US11766455B2 (en) * 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
SI3773689T1 (sl) * 2018-04-11 2023-02-28 Enterome S.A. Antigenski peptidi za preprečevanje in zdravljenje raka
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
GB2599510B (en) * 2019-04-05 2023-08-30 Earli Inc Improved methods and compositions for synthetic biomarkers
CA3137880A1 (en) 2019-05-28 2020-12-03 Rodrigo CEBALLOS LENTINI Systems and methods for processing images to prepare slides for processed images for digital pathology
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113388006A (zh) * 2020-03-18 2021-09-14 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
US11913023B2 (en) 2020-03-31 2024-02-27 Walking Fish Therapeutics, Inc. Modified B cells and methods of use thereof
KR20230006821A (ko) * 2020-03-31 2023-01-11 워킹 피쉬 테라퓨틱스 변형 b 세포 및 이의 사용 방법
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
KR20220022021A (ko) 2020-08-14 2022-02-23 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3190707A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
AU678483B2 (en) 1993-06-03 1997-05-29 Protherics Inc. Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JP4767371B2 (ja) 1996-01-17 2011-09-07 インペリアル・イノベイションズ・リミテッド 細胞障害性ｔリンパ球（ｃｔｌ）を用いた免疫療法
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) * 1996-04-24 2004-02-11 Akzo Nobel Nv Novel peptides suitable for use in antigen specific immunosuppressive therapy
CA2262007A1 (en) * 1996-07-22 1998-01-29 The Rockefeller University Env-glycoprotein vaccine for protection of htlv-i and -ii infection
AU6240798A (en) 1997-01-15 1998-08-07 Zymogenetics Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
EP0910641A1 (en) * 1997-02-13 1999-04-28 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU750358B2 (en) * 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO1999055380A1 (en) * 1998-04-27 1999-11-04 Pacific Northwest Cancer Foundation Nr-CAM GENE, NUCLEIC ACIDS AND NUCLEIC ACID PRODUCTS FOR THERAPEUTIC AND DIAGNOSTIC USES FOR TUMORS
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
US20020042386A1 (en) * 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2395827A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1294748B1 (en) 2000-03-27 2010-06-30 Technion Research and Development of Foundation, Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7083789B2 (en) * 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
CA2511927A1 (en) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Method of preparing a vaccine and anti-tumor vaccines
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
JP4579836B2 (ja) * 2004-01-23 2010-11-10 株式会社グリーンペプタイド 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
EP1642905B1 (en) * 2004-10-02 2009-01-21 Immatics Biotechnologies GmbH Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
US7902143B2 (en) * 2004-12-07 2011-03-08 Toray Industries, Inc. Cancer antigen peptide and the use thereof
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
ATE440107T1 (de) * 2005-09-05 2009-09-15 Immatics Biotechnologies Gmbh Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
ES2341802T3 (es) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
CA2625403A1 (en) 2005-10-17 2007-04-26 Institute For System Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008039874A2 (en) * 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008109757A2 (en) * 2007-03-06 2008-09-12 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
EP2280731A1 (en) * 2008-04-09 2011-02-09 Technion Research and Development Foundation, Ltd. Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
RS53782B1 (en) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
CN114057895A (zh) * 2014-05-28 2022-02-18 诺诺公司 TAT-NR2B9c的氯盐
PE20181897A1 (es) * 2016-04-21 2018-12-11 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cancer
JP7382310B2 (ja) * 2017-09-06 2023-11-16 カリフォルニア インスティチュート オブ テクノロジー シグナリング及び抗原提示の２機能性レセプター（ｓａｂｒ）

Also Published As

Publication number Publication date
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
KR20160103558A (ko) 2016-09-01
ES2536465T3 (es) 2015-05-25
EP2172211A1 (en) 2010-04-07
ES2584245T3 (es) 2016-09-26
JP2017018102A (ja) 2017-01-26
PL2331118T3 (pl) 2017-05-31
EP3120868A1 (en) 2017-01-25
EP3106175B1 (en) 2020-04-01
BRPI0920791B1 (pt) 2022-01-18
PL2172211T3 (pl) 2015-05-29
US20210238227A1 (en) 2021-08-05
US20160376316A1 (en) 2016-12-29
PT2172212T (pt) 2016-12-22
ES2708654T3 (es) 2019-04-10
HUE042115T2 (hu) 2019-06-28
CA2739387A1 (en) 2010-04-08
EA032437B1 (ru) 2019-05-31
CA2739384C (en) 2017-05-02
EP3120870B1 (en) 2020-04-01
HRP20182151T1 (hr) 2019-02-08
HRP20201015T1 (hr) 2020-10-16
CA2936868C (en) 2019-10-22
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
NZ591855A (en) 2012-11-30
SI3124043T1 (sl) 2020-07-31
DK2331118T3 (da) 2017-01-09
DK2172212T3 (da) 2016-12-19
CA2936869C (en) 2019-08-06
AU2009300087A1 (en) 2010-04-08
DK3069728T3 (en) 2019-02-25
CN106986919A (zh) 2017-07-28
RS55043B1 (sr) 2016-12-30
WO2010037514A3 (en) 2010-06-03
US20210261614A1 (en) 2021-08-26
HRP20150223T8 (hr) 2015-07-03
LT3132801T (lt) 2020-02-10
HUE049364T2 (hu) 2020-09-28
HRP20201015T8 (hr) 2022-01-21
US10941181B2 (en) 2021-03-09
KR101687840B1 (ko) 2016-12-19
CN102170901B (zh) 2015-01-07
DK3120869T3 (da) 2020-08-10
CA2936920C (en) 2019-12-03
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
CN102170900B (zh) 2016-10-26
US11136352B2 (en) 2021-10-05
HRP20150223T1 (hr) 2015-06-05
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
SI2172212T1 (sl) 2016-12-30
RS60338B1 (sr) 2020-07-31
EP2341927B1 (en) 2016-05-04
PT3120870T (pt) 2020-07-01
DK3111952T3 (en) 2019-01-28
HRP20201228T1 (hr) 2021-02-05
HUE049367T2 (hu) 2020-09-28
ES2607460T3 (es) 2017-03-31
AU2009300087B2 (en) 2014-09-04
KR102133402B1 (ko) 2020-07-14
EP3132801A1 (en) 2017-02-22
JP6294913B2 (ja) 2018-03-14
JP2017000148A (ja) 2017-01-05
US20160376313A1 (en) 2016-12-29
LT3111952T (lt) 2018-12-27
PT2172211E (pt) 2015-03-09
EP3106175A1 (en) 2016-12-21
US8895514B2 (en) 2014-11-25
TR201900809T4 (tr) 2019-02-21
US10047123B2 (en) 2018-08-14
SI3069728T1 (sl) 2019-03-29
JP2012504563A (ja) 2012-02-23
EP2331118A1 (en) 2011-06-15
LT2331118T (lt) 2016-12-27
CY1121098T1 (el) 2019-12-11
EP2172212A2 (en) 2010-04-07
JP2017018101A (ja) 2017-01-26
JP2012504393A (ja) 2012-02-23
HK1161106A1 (en) 2012-08-24
EP2341927A2 (en) 2011-07-13
ES2710608T3 (es) 2019-04-26
HUE030296T2 (en) 2017-04-28
EP2172212A3 (en) 2010-04-14
CA2936924C (en) 2019-07-16
SI3120870T1 (sl) 2020-08-31
CA2936982C (en) 2019-12-03
CY1123098T1 (el) 2021-10-29
RS58443B1 (sr) 2019-04-30
PL3124043T3 (pl) 2020-07-27
LT3120869T (lt) 2020-11-10
US20160376315A1 (en) 2016-12-29
EP3124043B1 (en) 2020-04-29
HRP20200110T1 (hr) 2020-05-15
EP2172212B1 (en) 2016-10-05
PT3132801T (pt) 2020-02-04
BRPI0920759A2 (pt) 2016-03-08
PT2341927T (pt) 2016-08-02
US20160355550A1 (en) 2016-12-08
US10906936B2 (en) 2021-02-02
US11208434B2 (en) 2021-12-28
ES2770090T3 (es) 2020-06-30
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
KR20220058655A (ko) 2022-05-09
EA201100586A1 (ru) 2011-10-31
DK2341927T3 (en) 2016-08-15
US20100158931A1 (en) 2010-06-24
HUE051030T2 (hu) 2021-01-28
EA023013B1 (ru) 2016-04-29
DK3106175T3 (da) 2020-06-22
JP6214066B2 (ja) 2017-10-18
ES2788129T8 (es) 2020-11-04
TR201900852T4 (tr) 2019-02-21
DK3120868T3 (da) 2020-06-22
LT3106175T (lt) 2020-08-10
RS58229B1 (sr) 2019-03-29
SI3120868T1 (sl) 2020-08-31
US20130309193A1 (en) 2013-11-21
US10046037B2 (en) 2018-08-14
MX2011003540A (es) 2011-06-20
JP6294914B2 (ja) 2018-03-14
CA2936870A1 (en) 2010-04-08
JP6297632B2 (ja) 2018-03-20
CA2936924A1 (en) 2010-04-08
JP2017029135A (ja) 2017-02-09
PL2341927T3 (pl) 2016-11-30
PT3111952T (pt) 2019-02-05
SI2331118T1 (sl) 2017-01-31
CA2936887C (en) 2019-11-12
EP3111952A1 (en) 2017-01-04
RS60385B1 (sr) 2020-07-31
US20210347822A1 (en) 2021-11-11
CA2936870C (en) 2019-11-26
SI3120869T1 (sl) 2020-10-30
KR20110082155A (ko) 2011-07-18
PL3132801T3 (pl) 2020-06-15
NZ624533A (en) 2015-09-25
PL3120868T3 (pl) 2020-08-24
JP5883476B2 (ja) 2016-03-15
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
ES2819244T3 (es) 2021-04-15
BRPI0920791A2 (pt) 2019-12-10
EA201401104A1 (ru) 2015-05-29
CA2936982A1 (en) 2010-04-08
CA2739387C (en) 2019-10-29
PL3111952T3 (pl) 2019-04-30
BRPI0920791B8 (pt) 2022-02-15
CA2936869A1 (en) 2010-04-08
EP3120868B1 (en) 2020-04-08
HK1159526A1 (zh) 2012-08-03
RS60386B1 (sr) 2020-07-31
PL2172212T3 (pl) 2017-04-28
LT3069728T (lt) 2019-02-11
HRP20200722T1 (hr) 2020-10-16
KR20180088494A (ko) 2018-08-03
RS60381B1 (sr) 2020-07-31
HUE050428T2 (hu) 2020-12-28
ES2802227T3 (es) 2021-01-18
US20120141517A1 (en) 2012-06-07
HRP20170115T1 (hr) 2017-03-24
PL3106175T3 (pl) 2020-08-24
EP2172211B1 (en) 2014-12-03
DK2172211T3 (en) 2015-02-16
US9993540B2 (en) 2018-06-12
US8653035B2 (en) 2014-02-18
MX338294B (es) 2016-04-11
EP3124043A1 (en) 2017-02-01
JP5753783B2 (ja) 2015-07-22
EP3120869B1 (en) 2020-07-22
HRP20201025T8 (hr) 2022-01-07
AU2009300088A1 (en) 2010-04-08
RS53782B1 (en) 2015-06-30
WO2010037513A1 (en) 2010-04-08
RS55531B1 (sr) 2017-05-31
US8318677B2 (en) 2012-11-27
CN102170901A (zh) 2011-08-31
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
JP2016047825A (ja) 2016-04-07
US20210253637A1 (en) 2021-08-19
ES2804723T3 (es) 2021-02-09
HRP20200988T1 (hr) 2020-10-16
JP2017023136A (ja) 2017-02-02
HRP20161504T1 (hr) 2016-12-30
US10227381B2 (en) 2019-03-12
CY1118702T1 (el) 2017-07-12
US20130004456A1 (en) 2013-01-03
US20150125478A1 (en) 2015-05-07
CY1123089T1 (el) 2021-10-29
CA2936887A1 (en) 2010-04-08
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
US10919931B2 (en) 2021-02-16
CY1123526T1 (el) 2022-03-24
HRP20190202T1 (hr) 2019-03-22
JP6367266B2 (ja) 2018-08-01
HRP20160915T1 (hr) 2016-10-07
EP2331118B1 (en) 2016-10-26
PT2331118T (pt) 2017-02-06
US8119139B2 (en) 2012-02-21
JP6150859B2 (ja) 2017-06-21
US20170326217A1 (en) 2017-11-16
PT3069728T (pt) 2019-02-13
US10047124B2 (en) 2018-08-14
SI3132801T1 (sl) 2020-03-31
SI3106175T1 (sl) 2020-08-31
WO2010037514A2 (en) 2010-04-08
CA2936920A1 (en) 2010-04-08
PL3120870T3 (pl) 2020-07-27
DK3120870T3 (da) 2020-06-22
UA110599C2 (uk) 2016-01-25
KR20110074894A (ko) 2011-07-04
CY1122913T1 (el) 2021-10-29
LT2172212T (lt) 2016-11-10
PT3120869T (pt) 2020-09-22
DK3132801T3 (da) 2020-02-10
EP3120869A1 (en) 2017-01-25
CA2739384A1 (en) 2010-04-08
NZ591882A (en) 2012-12-21
HUE031030T2 (en) 2017-06-28
NZ603016A (en) 2014-05-30
CY1116302T1 (el) 2017-02-08
PT3120868T (pt) 2020-07-16
JP2016145210A (ja) 2016-08-12
US20160376317A1 (en) 2016-12-29
KR102392070B1 (ko) 2022-04-29
US20190010190A1 (en) 2019-01-10
UA103202C2 (ru) 2013-09-25
US8961985B2 (en) 2015-02-24
KR101756488B1 (ko) 2017-07-11
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
EP3069728B1 (en) 2018-11-14
SI3111952T1 (sl) 2019-01-31
JP2014239681A (ja) 2014-12-25
ES2612466T3 (es) 2017-05-17
HUE041446T2 (hu) 2019-05-28
HUE049366T2 (hu) 2020-09-28
HUE047365T2 (hu) 2020-04-28
LT3120868T (lt) 2020-08-10
CY1122677T1 (el) 2021-03-12
KR101883426B1 (ko) 2018-07-31
RS55543B1 (sr) 2017-05-31
JP5855940B2 (ja) 2016-02-09
EP3069728A1 (en) 2016-09-21
CY1123113T1 (el) 2021-10-29
US20160376314A1 (en) 2016-12-29
KR20200085381A (ko) 2020-07-14
AU2009300088B2 (en) 2014-09-04
EP3132801B1 (en) 2019-10-30
CY1121258T1 (el) 2020-05-29
CA2936868A1 (en) 2010-04-08
PT3124043T (pt) 2020-05-12
PT3106175T (pt) 2020-07-01
HUE029360T2 (en) 2017-02-28
CN102170900A (zh) 2011-08-31
MX2011003539A (es) 2011-06-20
EP3120870A1 (en) 2017-01-25
EP3111952B1 (en) 2018-10-31
DK3124043T3 (da) 2020-05-04

Similar Documents

Publication Publication Date Title
CY1119744T1 (el) Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων
CY1119739T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων του εγκεφαλου
CY1117115T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
CY1117171T1 (el) Καινοτομα και ισχυρα πεπτιδια mch tαξης ιι προερχομενα απο την σουρβιβινη
CY1121691T1 (el) Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
MD3319985T2 (ro) Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva cancerului esofagian și a altor cancere
ATE512160T1 (de) T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
EA201892159A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака
CY1119253T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου
CY1124533T1 (el) Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων
CY1122083T1 (el) Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ)
EP2513136A4 (en) PEPTIDES TMEM22 AND VACCINES COMPRISING THEM
CY1116819T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και γαστρικου καρκινου